isotype control 13c4 Search Results


isotype control (13c4  (Sanofi)
90
Sanofi isotype control (13c4
A. Experimental outline for 1D11 experiments, athymic (left), BALB/c (right). B. Experimental outline for WT/TGF-βRIIMyeKO mice. C. Representative athymic x-ray images of early, middle and late disease. D. Representative BALB/c x-ray images of early, middle and late disease. E. Representative x-ray images of early, middle and late disease for WT/TGF-βRIIMyeKO mice. F. Western blot analysis from naïve BALB/c mice treated with <t>13C4</t> or 1D11. Spleen lysate from a mouse treated with 1D11 demonstrates a decrease in p-Smad 2/3 levels.
Isotype Control (13c4, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/isotype control (13c4/product/Sanofi
Average 90 stars, based on 1 article reviews
isotype control (13c4 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
control mouse igg1 isotype (clone 13c4) antibody  (Genzyme)
90
Genzyme control mouse igg1 isotype (clone 13c4) antibody
A. Experimental outline for 1D11 experiments, athymic (left), BALB/c (right). B. Experimental outline for WT/TGF-βRIIMyeKO mice. C. Representative athymic x-ray images of early, middle and late disease. D. Representative BALB/c x-ray images of early, middle and late disease. E. Representative x-ray images of early, middle and late disease for WT/TGF-βRIIMyeKO mice. F. Western blot analysis from naïve BALB/c mice treated with <t>13C4</t> or 1D11. Spleen lysate from a mouse treated with 1D11 demonstrates a decrease in p-Smad 2/3 levels.
Control Mouse Igg1 Isotype (Clone 13c4) Antibody, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/control mouse igg1 isotype (clone 13c4) antibody/product/Genzyme
Average 90 stars, based on 1 article reviews
control mouse igg1 isotype (clone 13c4) antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


A. Experimental outline for 1D11 experiments, athymic (left), BALB/c (right). B. Experimental outline for WT/TGF-βRIIMyeKO mice. C. Representative athymic x-ray images of early, middle and late disease. D. Representative BALB/c x-ray images of early, middle and late disease. E. Representative x-ray images of early, middle and late disease for WT/TGF-βRIIMyeKO mice. F. Western blot analysis from naïve BALB/c mice treated with 13C4 or 1D11. Spleen lysate from a mouse treated with 1D11 demonstrates a decrease in p-Smad 2/3 levels.

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: A. Experimental outline for 1D11 experiments, athymic (left), BALB/c (right). B. Experimental outline for WT/TGF-βRIIMyeKO mice. C. Representative athymic x-ray images of early, middle and late disease. D. Representative BALB/c x-ray images of early, middle and late disease. E. Representative x-ray images of early, middle and late disease for WT/TGF-βRIIMyeKO mice. F. Western blot analysis from naïve BALB/c mice treated with 13C4 or 1D11. Spleen lysate from a mouse treated with 1D11 demonstrates a decrease in p-Smad 2/3 levels.

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques: Western Blot

X-ray analysis of tumor-bearing mice at late stage disease prior to sacrifice. Representative images are from late stage disease. Formalin fixed tibias were scanned and analyzed by μCT as described in the methods section. Percent bone volume normalized to total volume (BV/TV) for each treatment group. A. Athymic mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing athymic mice treated with 1D11 have less osteolytic lesions than isotype control. B. Left: three-dimensional (3D) rendered μCT images from two tumor-bearing athymic mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease (TIBD) in the athymic mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. C. BALB/c mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing BALB/c mice treated with 1D11 have less osteolytic lesions than isotype control. D. Left: 3D rendered μCT images from two tumor-bearing BALB/c mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease in the BALB/c mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. E. WT/TGF-βRIIMyeKO mice mouse model: X-ray images, WT tumor (left), TGF-βRIIMyeKO tumor (right) and quantification of bone erosions. Tumor-bearing TGF-βRIIMyeKO have a reduced incidence of bone lesions as compared to tumor-bearing WT mice. F. Left: 3D rendered μCT images from two tumor-bearinF-βRIIMyeKO (right). Right: percent BV/TV over the course of tumor-induced bone disease in the WT/TGF-βRIIMyeKO mice mouse model. Tumor-bearing TGF-βRIIMyeKO mice only have a significant decrease in their overall bone volume at early disease. (9-13 tibias per group).

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: X-ray analysis of tumor-bearing mice at late stage disease prior to sacrifice. Representative images are from late stage disease. Formalin fixed tibias were scanned and analyzed by μCT as described in the methods section. Percent bone volume normalized to total volume (BV/TV) for each treatment group. A. Athymic mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing athymic mice treated with 1D11 have less osteolytic lesions than isotype control. B. Left: three-dimensional (3D) rendered μCT images from two tumor-bearing athymic mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease (TIBD) in the athymic mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. C. BALB/c mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing BALB/c mice treated with 1D11 have less osteolytic lesions than isotype control. D. Left: 3D rendered μCT images from two tumor-bearing BALB/c mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease in the BALB/c mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. E. WT/TGF-βRIIMyeKO mice mouse model: X-ray images, WT tumor (left), TGF-βRIIMyeKO tumor (right) and quantification of bone erosions. Tumor-bearing TGF-βRIIMyeKO have a reduced incidence of bone lesions as compared to tumor-bearing WT mice. F. Left: 3D rendered μCT images from two tumor-bearinF-βRIIMyeKO (right). Right: percent BV/TV over the course of tumor-induced bone disease in the WT/TGF-βRIIMyeKO mice mouse model. Tumor-bearing TGF-βRIIMyeKO mice only have a significant decrease in their overall bone volume at early disease. (9-13 tibias per group).

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques:

Tibal sections were stained with hematoxylin & eosin (H+E) for tumor burden analysis at late stage disease as described in the methods section. A&B. 4× magnification H+E sections from two tumor-bearing mice (athymic and BALB/c) at late stage disease, 13C4 treated (left), 1D11 treated (right) and quantification of percent tumor burden between treatment groups at late stage disease. Tumor-bearing mice (athymic and BALB/c) treated with 1D11 have a reduction in tumor burden as compared to isotype control. C. 4× magnification H+E sections from two tumor-bearing WT and TGF-βRIIMyeKO mice at late stage disease, WT (left), TGF-βRIIMyeKO (right) and quantification of percent tumor burden between mice at late stage disease. Tumor-bearing TGF-βRIIMyeKO mice have a reduction in tumor burden as compared to isotype control. T, Tumor. BM, Bone Marrow. Scale, 50 μm.

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: Tibal sections were stained with hematoxylin & eosin (H+E) for tumor burden analysis at late stage disease as described in the methods section. A&B. 4× magnification H+E sections from two tumor-bearing mice (athymic and BALB/c) at late stage disease, 13C4 treated (left), 1D11 treated (right) and quantification of percent tumor burden between treatment groups at late stage disease. Tumor-bearing mice (athymic and BALB/c) treated with 1D11 have a reduction in tumor burden as compared to isotype control. C. 4× magnification H+E sections from two tumor-bearing WT and TGF-βRIIMyeKO mice at late stage disease, WT (left), TGF-βRIIMyeKO (right) and quantification of percent tumor burden between mice at late stage disease. Tumor-bearing TGF-βRIIMyeKO mice have a reduction in tumor burden as compared to isotype control. T, Tumor. BM, Bone Marrow. Scale, 50 μm.

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques: Staining